Payload Information
General Information of This Payload
| Payload ID | PAY0AEZOS |
|||||
|---|---|---|---|---|---|---|
| Name | Topo1 inhibitor F |
|||||
| Synonyms |
Topo1 inhibitor F
Click to Show/Hide
|
|||||
| Target | DNA topoisomerase I (TOP1) | |||||
| Structure |
|
|||||
| Formula | C28H28FN3O6 |
|||||
| Isosmiles | C[C@H](O)CC(N[C@H]1CCC(C(C)=C(F)C=C2N=C3C4=CC([C@@]5(O)CC)=C6COC5=O)=C2C1=C3CN4C6=O)=O |
|||||
| PubChem CID | ||||||
| InChI |
InChI=1S/C28H28FN3O6/c1-4-28(37)17-8-21-25-15(10-32(21)26(35)16(17)11-38-27(28)36)24-19(30-22(34)7-12(2)33)6-5-14-13(3)18(29)9-20(31-25)23(14)24/h8-9,12,19,33,37H,4-7,10-11H2,1-3H3,(H,30,34)/t12-,19-,28-/m0/s1
|
|||||
| InChIKey |
NLPKXNVGNZKUTE-MVSLUWNJSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
521.545 |
Polar area |
130.75 |
||
Complexity |
1583.23321 |
xlogp Value |
2.40152 |
|||
Heavy Count |
38 |
Rot Bonds |
4 |
|||
Hbond acc |
8 |
Hbond Donor |
3 |
|||
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
WBP301088-X2 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
4.8 nM
|
Positive b7h3 expression (b7h3+++/++) | ||
| Method Description |
Anti-B7H3 ADC WBP301088-X2 was incubated with human tumor cells that positively expressed B7H3 for 7 days, and the inhibitory effect thereof on cell proliferation was assessed through a CellTiter-Glo@ chemiluminescence cell viability assay
|
||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1568 cells | CVCL_1476 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
11.4 nM
|
Positive b7h3 expression (b7h3+++/++) | ||
| Method Description |
Anti-B7H3 ADC WBP301088-X2 was incubated with human tumor cells that positively expressed B7H3 for 7 days, and the inhibitory effect thereof on cell proliferation was assessed through a CellTiter-Glo@ chemiluminescence cell viability assay
|
||||
| In Vitro Model | Minimally invasive lung adenocarcinoma | NCI-H358 cells | CVCL_1559 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
52.3 nM
|
Positive b7h3 expression (b7h3+++/++) | ||
| Method Description |
Anti-B7H3 ADC WBP301088-X2 was incubated with human tumor cells that positively expressed B7H3 for 7 days, and the inhibitory effect thereof on cell proliferation was assessed through a CellTiter-Glo@ chemiluminescence cell viability assay
|
||||
| In Vitro Model | Lung adenocarcinoma | Calu-6 cells | CVCL_0236 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
55.5 nM
|
Positive b7h3 expression (b7h3+++/++) | ||
| Method Description |
Anti-B7H3 ADC WBP301088-X2 was incubated with human tumor cells that positively expressed B7H3 for 7 days, and the inhibitory effect thereof on cell proliferation was assessed through a CellTiter-Glo@ chemiluminescence cell viability assay
|
||||
| In Vitro Model | Invasive breast carcinoma | MCF-7 cells | CVCL_0031 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
86.5 nM
|
Positive b7h3 expression (b7h3+++/++) | ||
| Method Description |
Anti-B7H3 ADC WBP301088-X2 was incubated with human tumor cells that positively expressed B7H3 for 7 days, and the inhibitory effect thereof on cell proliferation was assessed through a CellTiter-Glo@ chemiluminescence cell viability assay
|
||||
| In Vitro Model | Glioblastoma | U87 MG cells | CVCL_0022 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
164.7 nM
|
Positive b7h3 expression (b7h3+++/++) | ||
| Method Description |
Anti-B7H3 ADC WBP301088-X2 was incubated with human tumor cells that positively expressed B7H3 for 7 days, and the inhibitory effect thereof on cell proliferation was assessed through a CellTiter-Glo@ chemiluminescence cell viability assay
|
||||
| In Vitro Model | Amelanotic melanoma | A375 cells | CVCL_0132 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
180.8 nM
|
Positive b7h3 expression (b7h3+++/++) | ||
| Method Description |
Anti-B7H3 ADC WBP301088-X2 was incubated with human tumor cells that positively expressed B7H3 for 7 days, and the inhibitory effect thereof on cell proliferation was assessed through a CellTiter-Glo@ chemiluminescence cell viability assay
|
||||
| In Vitro Model | Prostate carcinoma | PC-3 cells | CVCL_0035 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
268.8 nM
|
Positive b7h3 expression (b7h3+++/++) | ||
| Method Description |
Anti-B7H3 ADC WBP301088-X2 was incubated with human tumor cells that positively expressed B7H3 for 7 days, and the inhibitory effect thereof on cell proliferation was assessed through a CellTiter-Glo@ chemiluminescence cell viability assay
|
||||
| In Vitro Model | Breast carcinoma | CAL-120 cells | CVCL_1104 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
369.3 nM
|
Positive b7h3 expression (b7h3+++/++) | ||
| Method Description |
Anti-B7H3 ADC WBP301088-X2 was incubated with human tumor cells that positively expressed B7H3 for 7 days, and the inhibitory effect thereof on cell proliferation was assessed through a CellTiter-Glo@ chemiluminescence cell viability assay
|
||||
| In Vitro Model | Lung adenocarcinoma | A549 cells | CVCL_0023 | ||
| Experiment 10 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
446 nM
|
Positive b7h3 expression (b7h3+++/++) | ||
| Method Description |
Anti-B7H3 ADC WBP301088-X2 was incubated with human tumor cells that positively expressed B7H3 for 7 days, and the inhibitory effect thereof on cell proliferation was assessed through a CellTiter-Glo@ chemiluminescence cell viability assay
|
||||
| In Vitro Model | Colon adenocarcinoma | HT-29 cells | CVCL_0320 | ||